Announcements Trials

Browse Landscape

Phase

Phase 2 20 Phase 1/2 5 Phase 1 4 Phase NA 2 Phase 3 1 Phase 2/3 1

Status

Completed 12 Terminated 4 Active not recruiting 4 Not yet recruiting 3 Recruiting 2 Withdrawn 1 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1 Carcinoma 1 Adenocarcinoma 1

Interventions

Cisplatin 130 Radiotherapy 94 Carboplatin 85 Paclitaxel 78 Fluorouracil 78 Cyclophosphamide 77 Gemcitabine 72 Capecitabine 66 Docetaxel 65 Doxorubicin 60 Oxaliplatin 59 Etoposide 57 Leucovorin 49 Vincristine 47 Chemotherapy, Adjuvant 42 Cytarabine 38 Dexamethasone 35 Drug Therapy 33 Bevacizumab 30 Epirubicin 29 Neoadjuvant Therapy 28 Pemetrexed 27 Tamoxifen 25 Prednisone 24 Irinotecan 24 Rituximab 21 Methotrexate 21 Radiotherapy, Intensity-Modulated 19 apatinib 18 Vinorelbine 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Unknown × regorafenib × Clear all

NCT02773524 2022-01-13

INTEGRATEIIa

Australasian Gastro-Intestinal Trials Group

Phase 3 Unknown

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡